| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | Stifel initiates coverage on Erasca stock with Buy rating, $4 price target | 1 | Investing.com | ||
| 03.09. | Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts | 3 | Seeking Alpha | ||
| 03.09. | BofA Securities downgrades Erasca stock to Underperform on competitive concerns | 6 | Investing.com | ||
| 18.08. | Morgan Stanley stuft Erasca-Aktie wegen verzögerter Studiendaten herab | 1 | Investing.com Deutsch | ||
| 18.08. | Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data | 1 | Investing.com | ||
| 12.08. | Erasca files $500M mixed securities shelf | 2 | Seeking Alpha | ||
| ERASCA Aktie jetzt für 0€ handeln | |||||
| 12.08. | Erasca, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Erasca, Inc.: Erasca Reports Second Quarter 2025 Business Updates and Financial Results | 224 | GlobeNewswire (Europe) | Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance... ► Artikel lesen | |
| 26.06. | Erasca, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Erasca Announces Clearance Of IND Application By FDA For ERAS-4001 | - | RTTNews | ||
| 02.06. | FDA clears Erasca's new cancer drug applications | 1 | Investing.com | ||
| 13.05. | Erasca, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Erasca, Inc.: Erasca Reports First Quarter 2025 Business Updates and Financial Results | 135 | GlobeNewswire (Europe) | Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026... ► Artikel lesen | |
| 13.05. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset | 1 | FierceBiotech | ||
| 13.05. | FDA clears Erasca's new cancer drug ERAS-0015 | 1 | Investing.com | ||
| 20.03. | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results | 650 | GlobeNewswire (Europe) | Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well... ► Artikel lesen | |
| 12.11.24 | Erasca, Inc.: Erasca Reports Third Quarter 2024 Business Updates and Financial Results | 569 | GlobeNewswire (Europe) | Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025     Strong execution... ► Artikel lesen | 
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | 0,00 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CUREVAC | 4,600 | -0,09 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More | ||
| NOVAVAX | 7,227 | -1,14 % | Novavax stock price target raised to $11 from $10 at H.C. Wainwright | ||
| NANOREPRO | 1,685 | -4,53 % | EQS-News: NanoRepro AG: Halbjahreszahlen 2025 - NanoRepro setzt Wachstumskurs fort | EQS-News: NanoRepro AG
 / Schlagwort(e): Halbjahresbericht
NanoRepro AG: Halbjahreszahlen 2025 - NanoRepro setzt Wachstumskurs fort 
31.10.2025 / 12:00 CET/CEST
Für den... ► Artikel lesen | |
| 4SC | 0,680 | -3,41 % | 4SC AG ringt um Zukunft nach schwerem Rückschlag | Das Biotech-Unternehmen 4SC AG (ISIN: DE000A3E5C40) aus Planegg-Martinsried steht an einem kritischen Wendepunkt. Nachdem die Europäische Arzneimittelbehörde EMA im Mai die Zulassung für das Krebsmedikament... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,040 | -1,92 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 1,251 | +7,47 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings  Company Exploring CDMO Expansion Opportunities in Southeast Asia  San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,460 | -4,56 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,504 | +3,67 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| DYNAVAX | 8,984 | -0,07 % | Dynavax Technologies: Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial | Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile  
   Newly presented data outline robust... ► Artikel lesen | |
| IBIO | 1,340 | 0,00 % | iBio, Inc. - 8-K, Current Report | ||
| REDHILL BIOPHARMA | 1,320 | -7,04 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen |